Evidence map›Paper›PMID 38168428›Full record

ArticlebioRxiv : the preprint server for biology2023

Imaging the master regulator of the antioxidant response in non-small cell lung cancer with positron emission tomography.

Hannah E Greenwood, Richard S Edwards, Will E Tyrrell, Abigail R Barber, Friedrich Baark, Muhammet Tanc, Eman Khalil, Aimee Falzone, Nathan P Ward, Janine M DeBlasi and 11 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

21 authors at 3 institutions in 2 countries.

Hannah E GreenwoodSchool of Biomedical Engineering & Imaging Sciences, King's College London, St Thomas' Hospital, London, SE1 7EH, UK.
Richard S EdwardsSchool of Biomedical Engineering & Imaging Sciences, King's College London, St Thomas' Hospital, London, SE1 7EH, UK.
Will E TyrrellSchool of Biomedical Engineering & Imaging Sciences, King's College London, St Thomas' Hospital, London, SE1 7EH, UK.
Abigail R BarberSchool of Biomedical Engineering & Imaging Sciences, King's College London, St Thomas' Hospital, London, SE1 7EH, UK.
Friedrich BaarkSchool of Biomedical Engineering & Imaging Sciences, King's College London, St Thomas' Hospital, London, SE1 7EH, UK.
Muhammet TancSchool of Biomedical Engineering & Imaging Sciences, King's College London, St Thomas' Hospital, London, SE1 7EH, UK.
Eman KhalilSchool of Biomedical Engineering & Imaging Sciences, King's College London, St Thomas' Hospital, London, SE1 7EH, UK.
Aimee FalzoneDepartment of Metabolism and Physiology, H. Lee Moffitt Cancer Center, Tampa, FL 33612, USA.
Nathan P WardDepartment of Metabolism and Physiology, H. Lee Moffitt Cancer Center, Tampa, FL 33612, USA.
Janine M DeBlasiDepartment of Metabolism and Physiology, H. Lee Moffitt Cancer Center, Tampa, FL 33612, USA.
Laura TorrenteDepartment of Metabolism and Physiology, H. Lee Moffitt Cancer Center, Tampa, FL 33612, USA.
David R PearceCRUK Lung Cancer Centre of Excellence, UCL Cancer Institute, University College London, WC1E 6DD, UK.
George FirthSchool of Biomedical Engineering & Imaging Sciences, King's College London, St Thomas' Hospital, London, SE1 7EH, UK.
Lydia M SmithSchool of Biomedical Engineering & Imaging Sciences, King's College London, St Thomas' Hospital, London, SE1 7EH, UK.
Oskar Vilhelmsson TimmermandSchool of Biomedical Engineering & Imaging Sciences, King's College London, St Thomas' Hospital, London, SE1 7EH, UK.
Ariana HuebnerCRUK Lung Cancer Centre of Excellence, UCL Cancer Institute, University College London, WC1E 6DD, UK.
Madeleine E GeorgeSchool of Biomedical Engineering & Imaging Sciences, King's College London, St Thomas' Hospital, London, SE1 7EH, UK.
Charles SwantonCRUK Lung Cancer Centre of Excellence, UCL Cancer Institute, University College London, WC1E 6DD, UK.
Robert E HyndsCRUK Lung Cancer Centre of Excellence, UCL Cancer Institute, University College London, WC1E 6DD, UK.
Gina M DeNicolaDepartment of Metabolism and Physiology, H. Lee Moffitt Cancer Center, Tampa, FL 33612, USA.
Timothy H WitneySchool of Biomedical Engineering & Imaging Sciences, King's College London, St Thomas' Hospital, London, SE1 7EH, UK.ORCID 0000-0002-9475-2873
St Thomas' Hospital · GBMoffitt Cancer Center · USThe Francis Crick Institute · GB

Funding

Investigation of NRF2-Dependent Metabolic LiabilitiesR37CA230042 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI DENICOLA, GINA MARIE · 2018 to 2024
$2.8M
NCI NIH HHS R37 CA230042Wellcome Trust CC2041
6 · The paper itself

Abstract

Mutations in the NRF2-KEAP1 pathway are common in non-small cell lung cancer (NSCLC) and confer broad-spectrum therapeutic resistance, leading to poor outcomes. The cystine/glutamate antiporter, system x

Identifiers

PMID38168428
PMCPMC10760199
OpenAlexW4389858654

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.